In a quiet corner of the Behman Hospital museum in Cairo, a glass ampoule of Delysid sits on display. The label on the vial, LSD, manufactured by Sandoz in the 1950s, marks a period when Egyptian psychiatrists were active participants in early consciousness research, working with the same compounds now driving renewed interest in psychedelic medicine worldwide.

That continuity is largely invisible today. Across the South-West Asian and North African (SWANA) region, mental health needs are significant and services remain limited, while drug laws range from strict to severe: possession carries heavy penalties in most countries, and trafficking is a capital offense in several. The gap between need and available treatment is real, and it shapes everything.

Still, the conversation is shifting. From regulatory discussions in Abu Dhabi to clinical work in Beirut, researchers, psychiatrists, and policymakers in the region are engaging seriously with psychedelic-assisted therapy, not as followers of a Western trend, but as practitioners with their own clinical realities, cultural frameworks, and historical precedents to draw from. Three distinct approaches are taking shape: the UAE's state-led regulatory interest, Lebanon's existing working model, and a broader cultural reassessment happening across the region. Only one of the three, Lebanon's, is actually treating patients right now. The other two are laying groundwork, and that's a different thing, worth saying plainly rather than blurring together.

Egypt's mental health sector is navigating familiar pressures: economic uncertainty, limited services, and the kind of stigma that keeps people from seeking care in the first place. It's a set of conditions most countries in the region would recognize. The data across SWANA points consistently to a treatment gap that is large relative to documented need.

Public surveys suggest that in many Arab countries, close to 30% of the population reports experiencing depression. In the UAE, a recent study found that 57.2% of residents had at least one diagnosable mental disorder. In Lebanon, the compounded effects of the 2020 Beirut port explosion and an ongoing economic crisis contributed to a 42% rise in suicides in July 2022 compared to the previous year. In Jordan, sustained refugee influxes from regional conflicts have placed additional pressure on an already stretched healthcare system.

This burden is not evenly distributed. Women across the region frequently navigate both cultural expectations around silence and a disproportionate exposure to domestic and political instability, making the decision to seek help a more complicated one for many.

The question isn't whether psychedelics can be halal, or permissible under Islamic law, but how. That's the discussion unfolding in religious and academic circles across the region, reframing these substances not as foreign intoxicants but as part of a longer, indigenous history.

Haya Al-Hejailan, a Saudi advocate and founder of the Arab Psychedelic Society, has been one of the more prominent voices making this case. In a 2023 interview with DoubleBlind Magazine, she argued that the region isn't importing anything new, that what's happening now is a revival of a practice that had disappeared under decades of religious conservatism and the West's own export of its drug war. In that same interview, she pointed to the region's pharmacopeia as evidence: the acacia tree, native across the Middle East, contains DMT, and Syrian rue carries MAOI properties comparable to the ayahuasca vine. “There's a long history of our ancestors experimenting with these plants,” she told DoubleBlind.

That history has material traces beyond her account. Rock art from the Tassili n'Ajjer site in Algeria, dating back some 9,000 years, depicts what is often interpreted as humanoid figures with mushroom-like heads and scenes suggesting ceremonial altered states. Sufi traditions have long used ecstatic chanting and movement to reach states of ego-dissolution that map closely onto what contemporary psychedelic research describes. And then there is Egypt's mid-twentieth century psychiatric research, a productive, internationally recognized body of work that predated the political and legal shifts that eventually shut down psychedelic science across much of the world.

That lineage does real work. It lets advocates frame psychedelic therapy as a recovery of existing knowledge rather than an imported trend, and that framing carries weight in conversations about Islamic law, or fiqh.

Some of that conversation has already played out in public. NPR profiled the debate in January 2025, and two voices from that reporting are worth bringing in here. Yasir Qadhi, chair of the Fiqh Council of North America, told NPR that “Technically, psychedelics don't fall under the exact same category as alcohol.” The reporter, not Qadhi, went on to explain the specific Quranic reasoning behind the alcohol prohibition. Qadhi himself stopped short of endorsing psychedelics' therapeutic value. Kamal Abu-Shamsieh, who directs the chaplaincy program at the Graduate Theological Union, made a related argument in the same piece: treating psychedelics as a medical question means asking about the patient and the evidence, he said, rather than starting from a blanket ruling on whether something is permitted. The Fiqh Council of North America's existing ruling permitting medical cannabis for serious conditions gives that argument a working precedent to point to.

Religious framing alone, though, won't resolve the practical gaps. That same NPR report featured Sughra Ahmed, a UK-based Muslim faith leader who took part in a psilocybin trial. She described the experience to NPR as meaningful, but she also pointed out how little of the existing therapeutic infrastructure, the music, the therapeutic language, the integration process, was built with a Muslim worldview in mind. She now runs monthly gatherings for Muslims to process psychedelic experiences through an Islamic cultural lens, an early example of what culturally grounded protocols might look like, built by and for the communities they're meant to serve.

Lebanon's psychiatrists didn't wait for policy reform, they worked within existing law. Since 2017, clinics at the American University of Beirut Medical Center and St. George Hospital have offered ketamine therapy for treatment-resistant depression and suicidal ideation, using a straightforward legal workaround: ketamine is classified as an anesthetic-dissociative rather than a psychiatric drug, which allows off-label prescription.

The clinical results have been meaningful. Dr. Farid Talih at AUBMC reports up to a 90% reduction in suicidal ideation among patients, and depression response rates ranging from 30 to nearly 90%. These programs treat depression and suicidal ideation as recognized psychiatric conditions. They are not marketed or structured as war trauma therapy, even though Lebanon's compounding crises, the port explosion, the currency collapse, the years of instability, are almost certainly part of what's driving demand. The distinction is worth holding onto: the clinical infrastructure exists and it works, but it wasn't built around conflict specifically.

Access remains a significant constraint. Sessions cost several hundred dollars per treatment, out of reach for most Lebanese, particularly given the economic collapse that has eroded the middle class. Political instability has also limited the model's reach beyond these two institutions. Still, Lebanon provides a concrete proof of concept: the legal and clinical groundwork is there, and it works.

The UAE is approaching psychedelic medicine the way it has approached other strategic sectors, as an area where early positioning could yield long-term advantages. The government's National Strategy for Wellbeing 2031 and the Federal Mental Health Law of 2024 have established a policy foundation. Government healthcare bodies including SEHA Mental Health Services have convened high-profile conferences in 2023 and 2024, bringing psychedelic science into formal institutional conversations. Clinics like The Valens Clinic in Dubai already offer esketamine for depression, demonstrating that psychedelic-adjacent treatment can operate within current frameworks.

The strategic logic is straightforward: the UAE wants to lead in medical tourism and next-generation healthcare, and psychedelic medicine is part of that calculus.

The regulatory picture, however, is more complicated. December 2025 amendments to the country's drug laws tightened penalties around controlled substances, creating uncertainty within the medical community. Several physicians exploring research programs have since adopted a wait-and-see posture, cautious about moving forward without clearer guidance. The UAE is simultaneously positioning for a psychedelic future and reinforcing its current prohibitionist framework. Whether formal research exceptions follow in the next two to three years will determine whether that positioning leads anywhere.

The most useful indicator of where the region's medical community stands may be a 2025 survey published in the Journal of Psychoactive Drugs, led by Jordanian physicians and researchers across multiple institutions. Nearly 2,000 Jordanian doctors and medical students were polled on their views of psychedelic therapy. Just over half, 50%, were opposed, 34.1% described themselves as cautious, and 15.5% were supportive. Professional seniority made no difference, professors were roughly as skeptical as students.

The figure advocates are focused on is that 34%. In a medical culture that places significant weight on clinical evidence and institutional authority, peer-reviewed efficacy data has a real chance of moving opinion. The survey's authors are directing their energy toward medical conferences and university lectures, presenting trial data from international research programs, and working with Jordan's network of over 30 mental health NGOs to build broader coalitions of support.

Jordan's situation illustrates a straightforward dynamic: the path to change runs through the medical establishment, and the medical establishment can be persuaded by evidence.

Egypt's engagement with psychedelic research is not a new idea, it's an interrupted one. In the 1950s and '60s, psychiatrists at Behman Hospital and the Greek Hospital in Cairo were conducting LSD research that put Egypt alongside Western institutions at the center of the field. That work stopped, and much of it has since been largely forgotten.

In documenting this history, I found that the infrastructure for a revival is more developed than it might appear. Egypt has 61 licensed mental health facilities and a Mental Health Act of 2009 that already provides frameworks for research. The more immediate constraints are workforce and resources: the country has 0.68 psychiatrists per 100,000 people and fewer than 120 clinical psychologists for a population exceeding 100 million.

Any viable path forward, as I detail in “Between East and West,” operates within existing legal and ethical boundaries, through education, historical documentation, and international collaboration rather than advocacy for illegal activity. Given Egypt's position as a cultural and intellectual reference point across the Arab world, meaningful movement there would likely carry weight elsewhere in the region.

One question comes up more than any other when people outside the region hear about this work: is any of this about war? Given how much of SWANA's recent history involves conflict, and given that psychedelic-assisted programs addressing war trauma elsewhere have gotten real international attention, it's a fair thing to ask.

The honest answer is mostly no, not yet, and not in the way people tend to imagine it. Lebanon's ketamine clinics, the closest thing the region has to an operating psychedelic-adjacent program, treat depression and suicidal ideation as clinical diagnoses. They are not publicly running as war trauma programs, and I haven't found verified evidence of a comparable initiative elsewhere in SWANA built specifically around conflict or displacement.

That doesn't mean the trauma isn't real. Beirut's port exploded in 2020. Jordan has absorbed large refugee populations from neighboring conflicts for years. Egypt sits next to more than one active conflict. None of that needs a footnote, it's daily life for a lot of people in the region. But there's a real difference between a population carrying trauma and a clinical system built to treat it with psychedelics specifically, and SWANA mostly hasn't built the second thing yet. What exists right now is psychiatric infrastructure responding to depression and suicidality, some of it almost certainly downstream of conflict and economic collapse, but organized around diagnosis, not around war.

If that changes, and there are researchers who think it should, it will most likely start in Lebanon, where the clinical relationships and the legal workaround already exist. For now, treating this as a war trauma story gets ahead of the evidence.

Progress across the region will not follow a single trajectory. Over the next year, ketamine-based treatment is likely to expand quietly into additional countries, following the clinical model Lebanon has already established. The UAE may announce formal research exceptions within two to three years, probably framed within a broader medical innovation initiative.

Longer-term, the cultural and educational groundwork matters as much as the regulatory work. Arabic-language educational materials on psychedelic science are beginning to be developed. Mental health professionals are starting to build culturally grounded therapeutic frameworks. The theological work, engaging Islamic scholars to issue formal fatwas on the medical use of psychedelics, is slow but already underway, shaped in part by thinkers like Qadhi and Abu-Shamsieh.

There are risks that aren't being discussed openly enough. The most significant is access. Without deliberate structural intervention, psychedelic therapy in the region could develop into a service available primarily to wealthy Gulf residents and international medical tourists, while people without resources remain outside the system entirely, and remain subject to criminal penalties for involvement with the same substances. The economics are stark: treatment costs are high, trained therapists are scarce, and the therapeutic protocols in use were largely designed elsewhere for different populations. As more regional practitioners travel abroad for training, there's a real question about whether they return to build local capacity or stay. The professionals most needed to develop a regionally grounded model may be the least likely to remain.

If psychedelic medicine in SWANA develops along the same lines as the broader healthcare system, well-resourced at the top, inaccessible to most, it won't have addressed the problem it set out to solve.

So, is the region ready? Not for anything like widespread psychedelic therapy, not yet. What exists is real: an active clinical program in Lebanon, growing medical interest in Jordan, state attention in the UAE, and a historical foundation in Egypt that's only just being recognized again. What's missing is just as real: consistent regulatory pathways, trained therapists in meaningful numbers, and a plan for who actually gets access when this scales. Readiness, in other words, is partial and uneven, and it's arriving country by country rather than as one regional wave.

That ampoule in Behman Hospital has been sitting there for half a century. As the region begins to engage with this history again, the more useful question isn't whether SWANA is ready for psychedelic medicine. It's whether the field, as it currently exists, is ready to engage with SWANA on its own terms.

Nader Wahba, M.A., is a clinical psychologist and researcher examining the history of medicine and psychiatry in Egypt. His work integrates transpersonal psychology, trauma studies, and cross-cultural perspectives.

💌 If you loved this email, forward it to a psychonaut in your life.

Editorial Process

DoubleBlind is a trusted resource for news, evidence-based education, and reporting on psychedelics. We work with leading medical professionals, scientific researchers, journalists, mycologists, indigenous stewards, and cultural pioneers. Read about our editorial policy and fact-checking process here.